Article

Phone calls, customized materials of limited value for glaucoma medication adherence

The use of telephone calls and customized printed materials may be of limited value in improving medication adherence in patients with glaucoma, according to results of a randomized, controlled clinical trial published online by the Archives of Ophthalmology.

Philadelphia-The use of telephone calls and customized printed materials may be of limited value in improving medication adherence in patients with glaucoma, according to results of a randomized, controlled clinical trial published online by the Archives of Ophthalmology.

Karen Glanz, PhD, MPH, of the University of Pennsylvania, Philadelphia, and colleagues enrolled 312 patients with glaucoma in the trial at two eye clinics at a Veterans Affairs Medical Center and a large public hospital. The patients (average age: nearly 63 years) were considered to be nonadherent because they did not take their medication, refill their prescriptions, and/or keep their medical appointments.

The treatment group received automated, interactive telephone calls and tailored printed materials, whereas the control group received usual care, which included the recommendation for medical appointments and prescription refills. Researchers measured adherence to medication-taking, prescription-refilling, and appointment-keeping based on interviews, medical charts, and other data.

“A statistically significant increase for all adherence measures was noted in both the treatment group and the control group in the I-SIGHT (Interactive Study to Increase Glaucoma Adherence to Treatment) trial. The treatment group had greater improvements in adherence in four of six categories, but this did not reach statistical significance,” the authors commented.

Researchers suggest that “motivated patients” in an ongoing clinical trial might improve their adherence to treatment even without customized messages for encouragement.

“New technologies, such as interactive voice recognition and electronic reminder devices, may play a supportive role in the effort to improve adherence in patients with glaucoma, but further study is warranted,” the authors concluded.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.